Please login to the form below
Zontivity
This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.
FDA reviewer backs approval of TMC's cangrelor
Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the
Latest news
-
R&D productivity takes off
Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
-
Orphan drugs in latest CHMP recommendations
s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
-
Merck's first-in-class Zontivity cleared in US
After a long haul, Merck &Co's Zontivity has become the first drug in the new protease-activated receptor-1 (PAR-1) antagonist class to be approved for marketing in the ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1
-
FDA panel backs Merck's vorapaxar
Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- Sinovac’s COVID-19 vaccine appears safe in older adults
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
